Exact Sciences, A Cathie Wood Stock, Surges As Rival Colon Cancer Test PalesInvestors Business Daily • 04/02/24
Exact Sciences Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-CancerBusiness Wire • 03/28/24
How Much Upside is Left in Exact Sciences (EXAS)? Wall Street Analysts Think 53.83%Zacks Investment Research • 03/25/24
Exact Sciences (EXAS) Up 4.2% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 03/22/24
The New England Journal of Medicine Publishes Cologuard Plus™ Test Results from Pivotal BLUE-C StudyBusiness Wire • 03/13/24
Cathie Wood Darling Exact Sciences Could Pop After Its Next-Gen Product OutperformsInvestors Business Daily • 03/13/24
Can Exact Sciences (EXAS) Climb 55.43% to Reach the Level Wall Street Analysts Expect?Zacks Investment Research • 03/08/24
Exact Sciences and Basketball Great Jamal Mashburn Encourage Americans 45+ to Have a Game Plan Against Colon CancerBusiness Wire • 03/07/24
Exact Sciences Launches Riskguard™ Hereditary Cancer Test in the United StatesBusiness Wire • 02/28/24